Meeting
2021 ASCO Annual Meeting
STK11/TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.
Authors
Abdul Rafeh Naqash
Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
Abdul Rafeh Naqash , Charalampos S. Floudas , Asaf Maoz , Joanne Xiu , Yasmine Baca , Jia Zeng , Chul Kim , Julia Judd , Luis E. Raez , Gilberto Lopes , Jorge J. Nieva , Hossein Borghaei , Wolfgang Michael Korn , Naoko Takebe , Stephen V. Liu , Hirva Mamdani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9087)
DOI
10.1200/JCO.2021.39.15_suppl.9087
Abstract #
9087
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
First Author: Petros Christopoulos
Poster
2023 ASCO Annual Meeting
Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).
First Author: Matthew James Hadfield
Poster
2020 ASCO Virtual Scientific Program
Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).
First Author: Stephen V. Liu
Poster
2024 ASCO Annual Meeting
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
First Author: Amin Nassar